Manulife or Sun Life: Which Finance Stock Is the Better Buy?
Manulife or Sun Life: Which Finance Stock Is the Better Buy?
Manulife Financial (TSX:MFC) and Sun Life Financial (TSX:SLF) are both powerhouses in the insurance world, with deep roots in Canada and expanding global footprints. Manulife's strength lies in its diverse business lines, with solid growth in wealth management and a large presence in Asia. Meanwhile, Sun Life shines with its strong position in group benefits and a growing asset management business. Both have strengths, but which is the better buy?
宏利金融(TSX:MFC)和永明金融(TSX:SLF)都是保險業的巨頭,在加拿大擁有深厚根基並不斷擴大全球版圖。 宏利的實力在於其多元化業務線,在财富管理領域實現穩健增長,並在亞洲擁有豐富的業務版圖。 與此同時,永明在集團福利方面處於強勢地位,並擁有不斷增長的資產管理業務。 兩者各有所長,但哪個更值得買入?
Manulife stock
宏利股票
Manulife has a lot going for it, especially after its second-quarter 2024 results. The company reported core earnings of $1.7 billion, reflecting a 6% year-over-year increase, along with a core earnings per share (EPS) of $0.91. Now up 9% from the same period last year. This was bolstered by strong performance in Asia, particularly in new business growth and value. However, net income remained flat at $1 billion. A key strength is the company's steady capital position, highlighted by a 139% LICAT ratio, which underscores its financial resilience. Plus, Manulife's aggressive share-buyback program, with $1.1 billion worth of shares repurchased so far, shows its commitment to returning value to shareholders.
宏利目前擁有諸多優勢,特別是在2024年第二季度業績公佈後。公司報告了17億美元的核心收入,同比增長6%,以及每股核心收益(EPS)達到0.91美元。 較去年同期增長9%。 這主要得益於亞洲業務的強勁表現,特別是新業務增長和價值方面。 然而,淨收入仍維持在10億美元水平。 其關鍵優勢在於公司穩健的資本狀況,139%的LICAt比率凸顯了其財務韌性。 此外,宏利的積極股份回購計劃,迄今已回購價值11億美元的股份,展示了其致力於爲股東創造價值的承諾。
Despite these strengths, Manulife does face some challenges. While the core earnings grew, the company experienced a decline in net inflows within its Global Wealth and Asset Management division. This could be an area of concern for investors, as it reflects potential headwinds in certain market segments. Furthermore, while Manulife is making strides in areas like reinsurance and new business growth, its reliance on the Asian market could pose risks if conditions become unfavourable.
儘管具有這些優勢,宏利也面臨一些挑戰。 儘管核心收入增長,但公司的全球財富和資產管理部門出現了淨流入下降。 這可能會讓投資者感到擔憂,因爲這反映了某些市場部門可能面臨的挑戰。此外,雖然宏利在再保險和新業務增長等領域取得進展,但如果條件變得不利,其對亞洲市場的依賴可能會帶來風險。
Looking ahead, Manulife seems well-positioned for growth, particularly with its focus on transformation into a higher-return, lower-risk business. The company's future looks bright, especially with the expansion of its business in Asia and continued focus on shareholder value. From a valuation perspective, Manulife trades at a forward price-to-earnings (P/E) of about 10.04, thus making it attractive for value investors, especially given its solid dividend yield of around 4%.
展望未來,宏利似乎在增長方面處於良好位置,特別是在轉型爲高回報、低風險業務方面。 公司的未來看起來光明,特別是隨着其在亞洲業務的擴張和對股東價值的持續關注。 從估值角度看,宏利的前瞻市盈率約爲10.04,這使其對價值投資者具有吸引力,特別是考慮到其約4%的高股息率。
Sun Life
太陽人壽
Sun Life Financial had a solid second quarter in 2024, with underlying net income rising 9% to $1 billion, demonstrating its strong fundamentals. A key strength lies in its diversified business segments, particularly wealth and asset management. This saw a $36 million boost in net income thanks to higher fee income in both Canada and Asia. Plus, Sun Life's group benefits and protection business in the U.S. showed robust growth, even though the dental segment experienced challenges. Despite this, overall business growth has helped Sun Life maintain momentum in competitive markets.
永明金融在2024年第二季度表現穩健,核心淨利潤增長9%至10億美元,展示出其堅實的基本面。其關鍵優勢在於多元化的業務板塊,特別是財富和資產管理。由於加拿大和亞洲的高收入費用,這兩個領域的淨收入增加了3600萬美元。此外,儘管牙科業務面臨挑戰,但永明金融在美國的集團福利和保障業務表現強勁增長。儘管如此,整體業務增長已幫助永明金融在競爭激烈的市場中保持勢頭。
On the downside, Sun Life faced some headwinds in its group health and protection segment. This saw a decline of $55 million due to less favourable results in U.S. dental services following Medicaid redeterminations. Moreover, its reported net income dropped slightly by 2% to $646 million, largely due to a restructuring charge aimed at improving productivity. This initiative is expected to generate $200 million in savings by 2026. So, while it impacted short-term earnings, the long-term outlook seems optimistic.
然而,永明金融在健康福利和保障業務領域面臨一些逆風。由於美國醫療保障重新評估後牙科服務不利,這導致淨收入下降5500萬美元。此外,由於旨在提高生產力的重組費用,其報告的淨利潤略微下降2%至64600萬美元。這項舉措預計將在2026年前創造20000萬美元的儲蓄。因此,儘管影響了短期收益,但長期前景看似樂觀。
Looking ahead, Sun Life remains a promising option for investors. Its strong capital position, demonstrated by a 150% LICAT ratio and a forward P/E of around 10.65, makes it an appealing investment. The company's focus on business growth in Asia and North America, combined with efforts to streamline operations, positions it well for the future. As interest rates stabilize, Sun Life's asset management and fee-related earnings are expected to continue driving growth.
展望未來,永明金融仍然是投資者的一個有前途選擇。其強勁的資本狀況,由150%的LICAt比率和約10.65的前向市盈率所證明,使其成爲一個吸引人的投資。該公司在亞洲和北美的業務增長重點,以及簡化運營的努力,使其爲未來做好了準備。隨着利率穩定,預計永明金融的資產管理和與費用相關的收入將繼續推動增長。
Foolish takeaway
愚蠢的帶走
Between Manulife and Sun Life, Sun Life might edge out as the better long-term option right now. Its strong growth in asset management, particularly in Asia, and focus on streamlining operations with significant cost savings expected by 2026 position it for steady future gains. While both companies offer solid dividends and international exposure, Sun Life's ability to generate higher returns on equity and maintain strong fundamentals despite some short-term restructuring gives it a slight advantage.
在宏利金融和永明金融之間,目前永明金融可能會成爲更好的長期選擇。其在資產管理方面的強勁增長,特別是在亞洲,以及專注於通過2026年節省重大成本的運營簡化,使其爲穩定未來收益做好準備。雖然兩家公司都提供穩固的股息和國際投資機會,但儘管一些短期重組,永明金融仍能產生較高的股本回報率並保持堅實基本面,這使其略佔優勢。
譯文內容由第三人軟體翻譯。